Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Slatter, Tania L ^a   Wilson, Michelle ^a,b   Tang, Chingwen ^b   Campbell, Hamish G ^c   Ward, Vernon K ^b   Young, Vivienne L ^b   Van Ly, David ^c   Fleming, Nicholas I ^a   Braithwaite, Antony W ^a,c,d   Baird, Margaret A ^a,d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Maurice Wilkins Center   (New Zealand)

Author keywords

Cytotoxic immune response; dendritic cells; interleukin 12; p53 tumor suppressor protein; tumor vaccination

Indexed keywords

CD11 ANTIGEN; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 12; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P53; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOLL LIKE RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BONE MARROW CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84961603893     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1112941     Document Type: Article

References (44)

1. R.Kushwah, J.Hu. Dendritic cell apoptosis: regulation of tolerance vs. immunity. J Immunol 2010; 185:795-802; PMID:20601611; http://dx.doi.org/10.4049/jimmunol.1000325.
2. M.Chen, J.Wang. Programmed cell death of dendritic cells in immune regulation. Immunol Rev 2010; 236:11-27; PMID:20636805; http://dx.doi.org/10.1111/j.1600-065X.2010.00916.x.
3. M.Oren. Decision making by p53: life, death and cancer. Cell Death Diff 2003; 10:431-42; PMID:12719720; http://dx.doi.org/10.1038/sj.cdd.4401183.
4. A.W.Braithwaite, J.A.Royds, P.Jackson. The p53 story: layers of complexity. Carcinogenesis 2005; 26:1161-9; PMID:15817608; http://dx.doi.org/10.1093/carcin/bgi091.
5. S.W.Lowe, T.Jacks, D.E.Housman, H.E.Ruley. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci U S A 1994; 91:2026-30; PMID:8134344; http://dx.doi.org/10.1073/pnas.91.6.2026.
6. H.Symonds, L.Krall, L.Remington, M.Saenz-Robles, S.Lowe, T.Jacks, T.Van Dyke. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994; 78:703-11; PMID:8069917; http://dx.doi.org/10.1016/0092-8674(94)90534-7.
7. T.L.Slatter, P.Ganesan, C.Holzhauer, R.Mehta, C.Rubio, G.Williams, M.Wilson, J.A.Royds, M.A.Baird, A.W.Braithwaite. p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death Diff 2010; 17:540-50; PMID:19779492; http://dx.doi.org/10.1038/cdd.2009.136.
8. A.R.Clarke, C.A.Purdie, D.J.Harrison, R.G.Morris, C.C.Bird, M.L.Hooper, A.H.Wyllie. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849-52; PMID:8479523; http://dx.doi.org/10.1038/362849a0.
9. S.W.Lowe, E.M.Schmitt, S.W.Smith, B.A.Osborne, T.Jacks. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362:847-9; PMID:8479522; http://dx.doi.org/10.1038/362847a0.
10. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004.
11. O.E.Rahma, E.Ashtar, M.Czystowska, M.E.Szajnik, E.Wieckowski, S.Bernstein, V.E.Herrin, M.A.Shams, S.M.Steinberg, M.Merino et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012; 61:373-84; PMID:21927947; http://dx.doi.org/10.1007/s00262-011-1100-9.
12. I.M.Svane, A.E.Pedersen, J.S.Johansen, H.E.Johnsen, D.Nielsen, C.Kamby, S.Ottesen, E.Balslev, E.Gaarsdal, K.Nikolajsen et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007; 56:1485-99; PMID:17285289; http://dx.doi.org/10.1007/s00262-007-0293-4.
13. J.Helft, J.Bottcher, P.Chakravarty, S.Zelenay, J.Huotari, B.U.Schraml, D.Goubau, E.S.C.Reis. GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. Immunity 2015; 42:1197-211; PMID:26084029; http://dx.doi.org/10.1016/j.immuni.2015.05.018.
14. Y.Xu, Y.Zhan, A.M.Lew, S.H.Naik, M.H.Kershaw. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol 2007; 179:7577-84; PMID:18025203; http://dx.doi.org/10.4049/jimmunol.179.11.7577.
15. S.J.Win, V.K.Ward, P.R.Dunbar, S.L.Young, M.A.Baird. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol Cell Biol 2011; 89:681-8; PMID:21221122; http://dx.doi.org/10.1038/icb.2010.161.
16. L.Ohl, M.Mohaupt, N.Czeloth, G.Hintzen, Z.Kiafard, J.Zwirner, T.Blankenstein, G.Henning, R.Forster. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 2004; 21:279-88; PMID:15308107; http://dx.doi.org/10.1016/j.immuni.2004.06.014.
17. K.J.Radford, K.M.Tullett, M.H.Lahoud. Dendritic cells and cancer immunotherapy. Curr Opin Immunol 2014; 27:26-32; PMID:24513968; http://dx.doi.org/10.1016/j.coi.2014.01.005.
18. J.M.Curtsinger, D.C.Lins, M.F.Mescher. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003; 197:1141-51; PMID:12732656; http://dx.doi.org/10.1084/jem.20021910.
19. C.S.Schmidt, M.F.Mescher. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J Immunol 2002; 168:5521-9; PMID:12023347; http://dx.doi.org/10.4049/jimmunol.168.11.5521.
20. Y.Zhan, Y.Xu, S.Seah, J.L.Brady, E.M.Carrington, C.Cheers, B.A.Croker, L.Wu, J.A.Villadangos, A.M.Lew. Resident and monocyte-derived dendritic cells become dominant IL-12 producers under different conditions and signaling pathways. J Immunol 2010; 185:2125-33; PMID:20644172; http://dx.doi.org/10.4049/jimmunol.0903793.
21. P.Secchiero, B.Toffoli, E.Melloni, C.Agnoletto, L.Monasta, G.Zauli. The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. Acta Diabetol 2013; 50:899-906; PMID:23615706; http://dx.doi.org/10.1007/s00592-013-0476-8.
22. S.N.Lim, S.Kuhn, E.Hyde, F.Ronchese. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy. J Immunother 2012; 35:670-9; PMID:23090076; http://dx.doi.org/10.1097/CJI.0b013e318270e135.
23. A.MartIn-Fontecha, S.Sebastiani, U.E.Hopken, M.Uguccioni, M.Lipp, A.Lanzavecchia, F.Sallusto. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003; 198:615-21; PMID:12925677; http://dx.doi.org/10.1084/jem.20030448.
24. C.Escribano, C.Delgado-Martin, J.L.Rodriguez-Fernandez. CCR7-dependent stimulation of survival in dendritic cells involves inhibition of GSK3beta. J Immunol 2009; 183:6282-95; PMID:19841191; http://dx.doi.org/10.4049/jimmunol.0804093.
25. A.T.Kamath, J.Pooley, M.A.O'Keeffe, D.Vremec, Y.Zhan, A.M.Lew, A.D'Amico, L.Wu, D.F.Tough, K.Shortman. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol 2000; 165:6762-70; PMID:11120796; http://dx.doi.org/10.4049/jimmunol.165.12.6762.
26. M.Chen, Y.H.Wang, Y.Wang, L.Huang, H.Sandoval, Y.J.Liu, J.Wang. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006; 311:1160-4; PMID:16497935; http://dx.doi.org/10.1126/science.1122545.
27. −2 controls dendritic cell longevity in vivo. J Immunol 2002; 169:3006-14; PMID:12218115; http://dx.doi.org/10.4049/jimmunol.169.6.3006.
28. E.Amiel, B.Everts, T.C.Freitas, I.L.King, J.D.Curtis, E.L.Pearce, E.J.Pearce. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol 2012; 189:2151-8; PMID:22826320; http://dx.doi.org/10.4049/jimmunol.1103741.
29. T.Yoshikawa, T.Niwa, H.Mizuguchi, N.Okada, S.Nakagawa. Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency. Gene Ther 2008; 15:1321-9; PMID:18480845; http://dx.doi.org/10.1038/gt.2008.85.
30. C.Gasparini, A.Tommasini, G.Zauli. The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation. Hum Immunol 2012; 73:342-5; PMID:22374325; http://dx.doi.org/10.1016/j.humimm.2012.01.018.
31. J.Cui, T.Shin, T.Kawano, H.Sato, E.Kondo, I.Toura, Y.Kaneko, H.Koseki, M.Kanno, M.Taniguchi. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278:1623-6; PMID:9374462; http://dx.doi.org/10.1126/science.278.5343.1623.
32. A.B.Pawlowska, S.Hashino, H.McKenna, B.J.Weigel, P.A.Taylor, B.R.Blazar. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood 2001; 97:1474-82; PMID:11222396; http://dx.doi.org/10.1182/blood.V97.5.1474.
33. D.Xu, P.Gu, P.Y.Pan, Q.Li, A.I.Sato, S.H.Chen. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 2004; 109:499-506; PMID:14991570; http://dx.doi.org/10.1002/ijc.11696.
34. A.V.Gudkov, K.V.Gurova, E.A.Komarova. Inflammation and p53: A Tale of Two Stresses. Genes Cancer 2011; 2:503-16; PMID:21779518; http://dx.doi.org/10.1177/1947601911409747.
35. M.Watanabe, K.D.Moon, M.S.Vacchio, K.S.Hathcock, R.J.Hodes. Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses. Immunity 2014; 40:681-91; PMID:24792911; http://dx.doi.org/10.1016/j.immuni.2014.04.006.
36. G.Di Minin, A.Bellazzo, M.Dal Ferro, G.Chiaruttini, S.Nuzzo, S.Bicciato, S.Piazza, D.Rami, R.Bulla, R.Sommaggio et al. Mutant p53 Reprograms TNF Signaling in Cancer Cells through Interaction with the Tumor Suppressor DAB2IP. Mol Cell 2014; 56:617-29; PMID:25454946; http://dx.doi.org/10.1016/j.molcel.2014.10.013.
37. M.M.Gubin, X.Zhang, H.Schuster, E.Caron, J.P.Ward, T.Noguchi, Y.Ivanova, J.Hundal, C.D.Arthur, W.J.Krebber et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81; PMID:25428507; http://dx.doi.org/10.1038/nature13988.
38. R.S.Herbst, J.C.Soria, M.Kowanetz, G.D.Fine, O.Hamid, M.S.Gordon, J.A.Sosman, D.F.McDermott, J.D.Powderly, S.N.Gettinger et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011.
39. M.Merad, P.Sathe, J.Helft, J.Miller, A.Mortha. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Ann Rev Immunol 2013; 31:563-604; PMID:23516985; http://dx.doi.org/10.1146/annurev-immunol-020711-074950.
40. H.Hochrein, K.Shortman, D.Vremec, B.Scott, P.Hertzog, M.O'Keeffe. Differential production of IL-12, IFN-α, and IFN-gamma by mouse dendritic cell subsets. J Immunol 2001; 166:5448-55; PMID:1313382; http://dx.doi.org/10.4049/jimmunol.166.9.5448.
41. J.M.den Haan, S.M.Lehar, M.J.Bevan. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192:1685-96; PMID:11120766; http://dx.doi.org/10.1084/jem.192.12.1685.
42. S.Kairouz, J.Hashash, W.Kabbara, W.McHayleh, I.A.Tabbara. Dendritic cell neoplasms: an overview. Am J Hematol 2007; 82:924-8; PMID:17636477; http://dx.doi.org/10.1002/ajh.20857.
43. K.A.McBride, M.L.Ballinger, E.Killick, J.Kirk, M.H.Tattersall, R.A.Eeles, D.M.Thomas, G.Mitchell. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 2014; 11:260-71; PMID:24642672; http://dx.doi.org/10.1038/nrclinonc.2014.41.
44. A.Porgador, J.W.Yewdell, Y.Deng, J.R.Bennink, R.N.Germain. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997; 6:715-26; PMID:9208844; http://dx.doi.org/10.1016/S1074-7613(00)80447-1.